Mario Hiroyuki Hirata is an expert in Biochemistry at Universidade de São Paulo (Brazil). As of October 2026, ScienceLeadR ranks Mario Hiroyuki Hirata in the top 1% of experts in Brazil for Lipid Metabolism Disorders. Mario Hiroyuki Hirata has authored 357 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 824 (community average: 125). How the SLR is computed.

LeadR Profile

Mario Hiroyuki Hirata Universidade de São Paulo Brazil
824 ScienceLeadR Reputation 824
Network Map

Biochemistry

Subspecialties: Genetics - Pharmacy - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026

Source: PubMed

Universidade de São Paulo

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 357

Citations

Citations: 6 440 1st author: 4 Last author: 70 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Induced mismatch repair deficiency: a hypothesis for the transient and reversible sensitization of mismatch repair-proficient tumors to Immune checkpoint blockade.
PMID 42923368 — dna mismatch repair, microsatellite repeats, cold temperature, neoplasms, therapeutics, microsatellite instability, msi-h
Front Immunol20260
Systems biology analysis reveals miRNA-mRNA networks associated with cardiomyocyte responses to SARS-CoV-2 infection.
PMID 42834098 — genes, sars-cov-2, fibrosis, micrornas, rna, messenger, systems biology, covid-19, severe acute respiratory syndrome-related coronavirus, infections, myocytes, cardiac
NPJ Syst Biol Appl20260
Meta-analysis of NPC2-mediated cholesterol transport in human cancers as a prognostic biomarker with therapeutic implications.
PMID 42775549 — neoplasms, biomarkers, cholesterol, precision medicine, therapeutics, stomach neoplasms, cell cycle
Cell Cycle20260
ADRB3, LEPR, FTO and PPARG variants contribute to obesity-related metabolic syndrome in Brazilian adults: a polygenic risk score approach.
PMID 42768086 — obesity, metabolic syndrome, genetic risk score
Int J Obes (Lond)20260
Immune checkpoint inhibitors in people living with HIV and cancer: a Kaplan-meier-derived individual patient data meta-analysis.
PMID 42423516 — safety, neoplasms, drug-related side effects and adverse reactions, immune checkpoint inhibitors, hiv
Expert Rev Anticancer Ther20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 4 1

By status:

Completed 2

By type:

Interventional 1
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map